Evidence map›Paper›PMID 42497260›Full record

ArticleScience advances2026

Interpretable dynamic quantitative vascular morphometry features using SHAP for anti-angiogenic therapy response prediction.

Kui Hu, Qian Cai, Jia Xu, Shuangquan Ai, Wuling Ou, Yulin Liu

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kui HuDepartment of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0002-0918-6310
Qian CaiThoracic Inner Department I, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0009-0008-5702-7585
Jia XuCollege of Biomedical Engineering, South-Central Minzu University, Wuhan, Hubei, China.ORCID 0009-0001-0545-3493
Shuangquan AiDepartment of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0009-0000-7334-0581
Wuling OuThoracic Inner Department I, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0002-1958-7062
Yulin LiuDepartment of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0003-1887-3769

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-angiogenic therapy benefits vary, with response rates of 40 to 70%, highlighting the need for early biomarkers to identify responders. We developed an automated machine learning framework that uses delta quantitative vascular morphometry features from standard contrast-enhanced CT to evaluate treatment response. This workflow combines automated tumor and vessel segmentation with feature extraction from routine scans for clinical use. Shapley additive explanations (SHAP)-based attributions identify key vascular and clinical features, providing meaningful, imaging-visible evidence aligned with therapy targets beyond traditional radiomics. Using baseline and follow-up CTs from 163 patients with lung cancer, we built three models using fivefold cross-validation, with the delta-merge model achieving high accuracy (area under the receiver operating characteristic curve = 0.842 internally, 0.806 externally). SHAP analysis uncovered an "arterial-dominant, venous-adaptive" pattern, where arterial involvement and venous recovery distinguish responders. This automated workflow and visualization support early, imaging-based response assessment and personalized treatment.

Indexed as

Angiogenesis InhibitorsLung NeoplasmsNeovascularization, PathologicFemaleHumansMachine LearningRadiomicsROC CurveTomography, X-Ray ComputedTreatment OutcomeAngiogenesis Inhibitors

Identifiers

PMID42497260
PMCPMC13398484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.